PD-L1 (B7-H1 or CD274), expressed on the surface of tumor cells as a ligand for PD-1, can inhibit T cell activation and negatively regulate the adaptive immune response, thereby enabling tumors to evade immune surveillance (7). This evidence concerns the gene PDCD1 and neoplasm.